Vivo funds buy 249,227 InMed Pharmaceuticals shares
InMed Pharmaceuticals Inc. reported significant insider buying by entities associated with Vivo Opportunity.
Rhea-AI Filing Summary
InMed Pharmaceuticals Inc. reported significant insider buying by entities associated with Vivo Opportunity. Over multiple open-market purchases from May 20 to June 8, 2026, Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P. acquired a combined 249,227 common shares at prices generally between $1.42 and $1.75 per share. The funds’ general partners, Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, are listed as reporting persons but each disclaims beneficial ownership beyond its pecuniary interest.
Positive
- None.
Negative
- None.
Insights
Vivo-associated funds steadily bought InMed shares in open-market trades.
Entities linked to Vivo Opportunity, as ten percent owners, executed 18 open-market purchases of InMed Pharmaceuticals common shares between May 20, 2026 and June 8, 2026. The Form 4 shows a net acquisition of 249,227 shares, with no reported sales in this period.
Transactions occurred at weighted average prices within ranges from about $1.42 to $1.75 per share, indicating gradual accumulation rather than a single block trade. The filing also notes that Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC act as general partners and disclaim full beneficial ownership beyond their pecuniary interest.
Because this is a secondary-market purchase, there is no direct cash impact on InMed itself. The informational value lies in a large shareholder increasing its stake, though the filing does not quantify the percentage of total shares outstanding, so the broader impact on ownership structure is not specified here.
Insider Trade Summary
Net Buyer: 249,227 shares
Net Buy
18 txns
Insider
Vivo Opportunity, LLC, Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity Cayman, LLC, Vivo Opportunity Cayman Fund, L.P.
Role
10% Owner | 10% Owner | 10% Owner | 10% Owner
Bought
249,227 shs ($392K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Shares | 29,518 | $1.52 | $45K |
| Purchase | Common Shares | 2,982 | $1.52 | $5K |
| Purchase | Common Shares | 49,966 | $1.57 | $78K |
| Purchase | Common Shares | 5,045 | $1.57 | $8K |
| Purchase | Common Shares | 6,125 | $1.57 | $10K |
| Purchase | Common Shares | 618 | $1.57 | $970.26 |
| Purchase | Common Shares | 7,069 | $1.55 | $11K |
| Purchase | Common Shares | 714 | $1.55 | $1K |
| Purchase | Common Shares | 20,753 | $1.52 | $32K |
| Purchase | Common Shares | 2,095 | $1.52 | $3K |
| Purchase | Common Shares | 14,838 | $1.55 | $23K |
| Purchase | Common Shares | 1,498 | $1.55 | $2K |
| Purchase | Common Shares | 16,164 | $1.57 | $25K |
| Purchase | Common Shares | 1,632 | $1.57 | $3K |
| Purchase | Common Shares | 30,882 | $1.69 | $52K |
| Purchase | Common Shares | 3,118 | $1.69 | $5K |
| Purchase | Common Shares | 51,056 | $1.56 | $80K |
| Purchase | Common Shares | 5,154 | $1.56 | $8K |
Holdings After Transaction:
Common Shares — 718,444 shares (Indirect, By Vivo Opportunity Fund Holdings, L.P.);
Common Shares — 72,535 shares (Indirect, By Vivo Opportunity Cayman Fund, L.P.)
Footnotes (11)
- F1. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P., the record holder of the securities. Vivo Opportunity, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- F2. Vivo Opportunity Cayman, LLC is the general partner of Vivo Opportunity Cayman Fund, L.P., the record holder of the securities. Vivo Opportunity Cayman, LLC disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- F3. The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.42 to $1.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (3) to this Form 4.
- F4. The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4.
- F5. The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (5) to this Form 4.
- F6. The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (6) to this Form 4.
- F7. The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.49 to $1.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (7) to this Form 4.
- F8. The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.50 to $1.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (8) to this Form 4.
- F9. The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.55 to $1.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (9) to this Form 4.
- F10. The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.53 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (10) to this Form 4.
- F11. The price reported herein is a weighted average price. These shares were acquired on the open market in multiple transactions at prices ranging from $1.48 to $1.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (11) to this Form 4.
Key Figures
Net shares bought: 249,227 shares
Number of purchase transactions: 18 trades
Price range (footnote F3): $1.42–$1.70/share
+3 more
6 metrics
Net shares bought
249,227 shares
Total open-market purchases reported in Form 4
Number of purchase transactions
18 trades
Open-market buy transactions between May 20 and June 8, 2026
Price range (footnote F3)
$1.42–$1.70/share
Weighted average price range for certain acquired shares
Price range (footnote F4)
$1.53–$1.75/share
Weighted average price range for another group of purchases
Holdings after trades – Fund Holdings L.P.
718,444 shares
InMed common shares held indirectly by Vivo Opportunity Fund Holdings, L.P.
Holdings after trades – Cayman Fund L.P.
72,535 shares
InMed common shares held indirectly by Vivo Opportunity Cayman Fund, L.P.
Key Terms
open-market purchase, weighted average price, beneficial ownership, pecuniary interest, +1 more
5 terms
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
weighted average price financial
"The price reported herein is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership financial
"disclaims beneficial ownership over such securities except to the extent of its pecuniary interest"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
pecuniary interest financial
"disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein"
ten percent owner financial
""is_ten_percent_owner": 1"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Over what dates did the InMed (INM) insider purchases by Vivo Opportunity occur?
The reported purchases occurred between May 20, 2026 and June 8, 2026. During this window, Vivo Opportunity–linked funds executed multiple open-market trades, gradually increasing their indirect ownership of InMed Pharmaceuticals common shares.
Are these InMed (INM) insider trades open-market purchases or another type of transaction?
All reported transactions are classified as open-market purchases of InMed common shares, coded "P" on Form 4. The filing specifies they were acquired in multiple market trades, with prices reported as weighted averages across each day’s executions.
Do Vivo Opportunity general partners claim full beneficial ownership of these InMed (INM) shares?
No. The Form 4 states that Vivo Opportunity, LLC and Vivo Opportunity Cayman, LLC, as general partners, disclaim beneficial ownership of the reported InMed shares except to the extent of their pecuniary interest in the respective limited partnerships.
AI-generated analysis. How Rhea-AI works. Not financial advice.
